Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Roxithromycin

Hazard 6* P 3* B 0 T 3 Risk See below

Information

Concentrations of roxithromycin in swedish wastewater treatment plants is likely to select for bacterial resistance. Can cooperate in the environment with other macrolide antibiotics, e.g. azithromycin, erythromycin and clarithromycin.

Roxithromycin is included in the Stockholm County Council's table of pharmaceuticals with risk for negative environmental impact according to the environmental program 2017–2021.

Studies have shown that even low concentrations of antibiotics in the environment may trigger antibiotic resistance and therefore measures should be taken to ensure that as little as possible ends up in our environment.

Suggestions on how to reduce the release of roxithromycin

Concrete proposals on how to work to reduce emissions of environmentally harmful pharmaceuticals on the list have been developed in close cooperation with the Stockholm Drug and Therapeutics Committee's expert advice. The action proposals were developed from an environmental perspective. The patient's best always goes first and several pharmaceuticals on the list are also included in the Wise list. However, for such pharmaceuticals, there may be measures that could reduce the environmental impact.

Concrete proposal for roxithromycin

  • Roxithromycin is not recommended in the Wise list.
  • For antibiotics, the general rule is as restrictive use as possible without risking the patient's health. Relevant cultivation is important in order to choose antibiotics that have a good effect with as narrow spectrum as possible.

The risk classification insignificant, according to Fass.se, is based on total sold amount (kg) of the substance in Sweden during the year 2015 and the toxicity of the substance, i.e. consideration has not been given to measured levels in the environment.

Author: The Pharmaceutical unit of Region Stockholm